News

The enrollment in the US has reached 36 patients, exceeding the minimum of 30 patients proposed by the United States Food and Drug Administration (FDA). The last patient

ALKS 7119 is being developed for the treatment of agitation in patients with Alzheimer’s disease and other central nervous system (CNS) indications. Based on initial blinded data from

The facility will supply RNAi therapeutics for Alnylam’s clinical and commercial needs. The location, selected in close collaboration with Commonwealth and local officials, demonstrates Alnylam’s ongoing commitment to

Therabron Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human CC10 protein which has potential clinical applications, based on its potent anti-inflammatory properties, in a

The deal gives AbbVie rights to Stemcentrx’s experimental treatment for a form of lung cancer and other experimental drugs. Stemcentrx’s lead late-stage asset rovalpituzumab tesirine (Rova-T) is presently

The phase IIb trial is a global multicentric study, randomized versus placebo, started in October last year in Lupus. It intends to assess the biological and clinical efficacy

Medivation develops and commercializes medically innovative therapies to treat severe diseases for which there are limited treatment options. The company has one marketed prostate cancer therapy, Xtandi, and

Lonsurf is indicated to treat adult patients with mCRC who have earlier been treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based

The US Food and Drug Administration (FDA) has cleared Cumberland’s investigational new drug application (IND) for Phase II clinical program for Vasculan in patients with systemic sclerosis. "Cumberland